Innovation
To solve the bottleneck problems in AAV gene therapy and find more and better cures for patients
Quality
Provide consistent, high quality, affordable AAV products, AAV services and technologies
AAV Expert
Dream to serve the community, promote and lead the future of AAV gene therapy
Growth
Aiming to grow both as individuals and as a company
Our Goals
Increase AAV gene therapy efficacy, decrease the cost, make it accessible and affordable to patients.
Key AAV Technologies to Solve the Bottlenecks
AAVone and AAVdual Production Systems
AAVnerGene developed innovative technologies to improve AAV production. One of our key developments is the mini-pHelper, which is a smaller size plasmid (8.4kb) that provides Ad helper functions in triple-plasmid (AAVtri) system with higher package efficiency compared to other Ad Helper plasmids. Based on the mini-pHelper, AAVnerGene has developed a two-plasmid (AAVdual) and a single-plasmid (AAVone) systems for AAV production, which could significantly increase AAV package efficacy and decrease the cost.
ATHENA AAV Capsid Platforms
ATHENA-I platform is used to systematically evaluate different AAV serotypes or variants by using Barcode-Seq technology.
ATHENA-II platform is designed to evolve novel AAV capsid with tissue-specific tropism from high complexity random peptide insert library.
ATHENA-III is a rational DNA shuffling library used to create novel hybrid AAV capsids.
By combining the three sub-platforms with AI, the ATHENA platform can efficiently identify, evolve and create the best AAV capsids for specific applications, potentially improving the effectiveness of gene therapy and reducing costs.